LHLaia Hernandez-Oller

Laia Hernandez-Oller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laia Hernandez-Oller has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Novel Carbon-Fiber Rigid Fixation for Sternal Closure

    by Alessandro Affronti, Blanca Domenech-Ximenos, Núria Pichel, Alba Ricarte, Laia Hernández, Brayan Rubio, Belén Cevallos, Marcelo Sanchez, Manuel Castellà

  • Open Access

    Extracellular Vesicles as Drug Delivery Systems in Cancer

    by Laia Hernandez-Oller, Joaquin Seras-Franzoso, Fernanda Andrade, Diana Rafael, Ibane Abasolo, Petra Gener, Simo Schwartz Jr.

    Within tumors, Cancer Stem Cell (CSC) subpopulation has an important role in maintaining growth and dissemination while preserving high resistance against current treatments. It has been shown that, when CSCs are eliminated, the surrounding Differentiated Cancer Cells (DCCs) may reverse their phenotype and gain CSC-like features to preserve tumor progression and ensure tumor survival. This strongly suggests the existence of paracrine communication within tumor cells. It is evidenced that the molecular crosstalk is at least partly mediated by Extracellular Vesicles (EVs), which are cell-derived membranous nanoparticles that contain and transport complex molecules that can affect and modify the biological behavior of distal cells and their molecular background. This ability of directional transport of small molecules prospects EVs as natural Drug Delivery Systems (DDS). EVs present inherent homing abilities and are less immunogenic than synthetic nanoparticles, in general. Currently, strong efforts are focused into the development and improvement of EV-based DDS. Even though EV-DDS have already reached early phases in clinical trials, their clinical application is still far from commercialization since protocols for EVs loading, modification and isolation need to be standardized for large-scale production. Here, we summarized recent knowledge regarding the use of EVs as natural DDS against CSCs and cancer resistance.